Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2024 | Transplantation in elderly patients with multiple myeloma without access to new drugs

Phillip Scheinberg • 7 Sep 2024
SOHO 2024
Multiple Myeloma

Phillip Scheinberg, MD, PhD, Beneficencia Portuguesa de Sao Paulo, São Paulo, Brazil, discusses the use of transplantation in elderly patients with multiple myeloma in Brazil, where access to other therapies is limited. Dr Scheinberg says that this treatment option is viable and effective in this patient population, with relatively low treatment-related mortality. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Phillip Scheinberg

Access to therapy for indolent lymphomas in Latin America 2:14
Access to therapy for indolent lymphomas in Latin America
Phillip Scheinberg • 7 Sep 2024
Transplantation for AL amyloidosis is associated with low mortality rates at a center in Brazil 1:23
Transplantation for AL amyloidosis is associated with low mortality rates at a center in Brazil
Phillip Scheinberg • 7 Sep 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals